Quick Answer: GLP-1 is a hormone your intestinal cells produce naturally in response to food, gut bacteria, and specific dietary compounds. You can meaningfully support GLP-1 production through soluble fermentable fiber, high-protein meals, gut microbiome optimization (especially Akkermansia muciniphila), and targeted supplementation including berberine and a synbiotic. The effects are real — and modest compared to GLP-1 receptor agonist drugs. That honest framing is what makes this guide useful.

GLPLUS+ Akkermansia GLP-1 gummies on white Carrara marble with pineapple mango gummies and lemon

GLP-1 receptor agonist drugs work. The clinical evidence is overwhelming — semaglutide and tirzepatide produce weight loss outcomes that the field has never seen before from a pharmacological intervention, with meaningful cardiovascular and metabolic benefits beyond the scale. That is not in dispute.

But not everyone wants them. Not everyone can access them. Insurance coverage remains inconsistent, injection anxiety is real, the side effect profile matters to many people, and the economics of indefinite use on a drug that likely needs to be continued to maintain results is a legitimate consideration.

And even for people who do use GLP-1 receptor agonists — understanding the underlying system those drugs amplify is worth doing. The biology of natural GLP-1 secretion does not stop mattering because a drug is artificially stimulating the receptor. In fact, optimizing the natural pathway can support better metabolic outcomes whether or not pharmaceutical GLP-1 therapy is part of the picture.

This guide is the complete protocol for supporting the GLP-1 pathway through the mechanisms the body already has: dietary inputs, gut bacteria, and targeted supplementation. No prescriptions, no injections, honest expectations.

How Natural GLP-1 Production Works

GLP-1 (glucagon-like peptide 1) is a hormone produced by L-cells — specialized enteroendocrine cells located primarily in the distal small intestine and colon. When you eat, L-cells detect nutrients and bacterial metabolites and release GLP-1 into the portal circulation.

GLP-1's primary effects once released:

  • Insulin secretion: GLP-1 stimulates pancreatic beta cells to release insulin in a glucose-dependent manner (only when blood glucose is elevated — this is why GLP-1 does not cause hypoglycemia)
  • Glucagon suppression: Inhibits glucagon release from alpha cells, reducing hepatic glucose output
  • Gastric emptying: Slows gastric motility, extending satiety and blunting post-meal glucose spikes
  • CNS appetite regulation: Acts on the hypothalamus and brainstem through vagal afferents to reduce appetite and increase satiety signaling
  • Gut barrier support: Promotes intestinal epithelial integrity

Under natural conditions, GLP-1 has a half-life of only 1–2 minutes — it is rapidly degraded by DPP-4 enzymes. GLP-1 receptor agonist drugs evade this degradation. Natural GLP-1 works in brief, meal-synchronized pulses rather than the sustained pharmacological levels produced by injectable GLP-1 agonists.

The key input pathways for natural GLP-1 secretion:

1. The SCFA pathway: Dietary fermentable fiber is metabolized by gut bacteria into short-chain fatty acids (SCFAs) — primarily butyrate, propionate, and acetate. SCFAs activate free fatty acid receptors FFAR2 and FFAR3 on L-cells, directly stimulating GLP-1 release. This is the single most important chronic lever for supporting GLP-1 production.

2. Akkermansia muciniphila P9 protein pathway: Akkermansia releases a surface protein called P9 that interacts with intestinal epithelial ICAM-2 receptors, enhancing GLP-1 secretion and improving glucose homeostasis. This mechanism was characterized in a landmark 2019 Plovier et al. study — and it is part of why Akkermansia abundance correlates with better metabolic health in human studies.

3. Direct L-cell nutrient sensing: Proteins (via amino acid receptors), fats (via FFAR1/GPR40), and to a lesser extent glucose directly stimulate L-cell GLP-1 release. High-protein meals are among the strongest acute GLP-1 secretagogues.

4. Bile acid pathway: Secondary bile acids produced by gut bacteria activate TGR5 receptors on L-cells, stimulating GLP-1 secretion. This pathway explains part of the gut microbiome's influence on metabolic health — and part of how bariatric surgery produces dramatic metabolic improvements beyond caloric restriction alone.

Multiple input channels means multiple places to intervene. The protocol targets all of them.

Why Natural Approaches Work Differently Than Drugs

This section matters because clarity here prevents disappointment — and disappointment from mismatched expectations is what sends people looking for the next thing rather than staying consistent with what actually works.

GLP-1 receptor agonist drugs produce supratherapeutic receptor stimulation. Semaglutide, for example, has a half-life of approximately one week and maintains GLP-1 receptor activation at levels far above the physiological pulses produced by natural GLP-1 secretion. The receptor is continuously stimulated at pharmacological concentrations. This produces dramatic appetite suppression, significant gastric emptying delay, and the weight loss outcomes seen in clinical trials.

Natural GLP-1 support raises the body's own GLP-1 production — but the ceiling is physiological production capacity. You can meaningfully increase your GLP-1 response to meals, improve Akkermansia abundance (which enhances GLP-1 secretion), and optimize the SCFA pathway. You cannot produce continuous pharmacological GLP-1 receptor stimulation through dietary and supplement means alone.

What natural GLP-1 support can realistically deliver: - Improved post-meal glucose management (reduced glucose spikes, better glycemic variability) - Reduced between-meal hunger and improved satiety signaling over 4–8 weeks of consistent gut microbiome support - Better metabolic flexibility (the ability to shift between glucose and fat as fuel sources) - Modest weight management support in the context of caloric awareness — not the 10–15% weight loss seen with pharmaceutical GLP-1 agonists - Improved gut barrier integrity and microbiome diversity with systemic downstream benefits

The accurate framing: this is supporting a real, important biological system. The benefits are real. They are not Ozempic equivalents, and any protocol or product that claims otherwise is not being honest with you.

With that settled — here is how to make the most of the natural pathway.

Dietary Foundation: The Non-Negotiables

Diet provides the substrate for everything downstream in this protocol. Get this layer wrong and no supplement stack will compensate for it.

Soluble Fermentable Fiber — The Most Important Lever

Fermentable fiber is the primary fuel source for SCFA-producing gut bacteria. Without adequate daily fermentable fiber, Akkermansia and the bacteria that produce butyrate, propionate, and acetate cannot thrive — and the SCFA → FFAR2/3 → L-cell → GLP-1 pathway runs at reduced capacity.

The most evidence-supported fermentable fiber sources:

  • Oat beta-glucan: A meta-analysis of controlled trials found consistent post-meal GLP-1 elevation with beta-glucan supplementation. Beta-glucan is a viscous soluble fiber that slows gastric emptying and provides fermentable substrate. Dose: 3–6g/day from oats or isolated supplement.
  • Inulin and FOS (fructooligosaccharides): The preferred prebiotic substrate for Bifidobacterium and a significant driver of Akkermansia abundance. Found naturally in chicory root, garlic, onions, leeks, asparagus, and Jerusalem artichoke. Can also be supplemented as inulin powder (5–10g/day).
  • Resistant starch: Starch that resists small intestinal digestion and reaches the colon intact for fermentation. Sources: cooled cooked potatoes (cooling converts some digestible starch to resistant starch), green banana flour, cooked and cooled legumes, unmodified potato starch (raw). Dose: 10–20g/day. Introduce gradually to avoid gas and bloating.
  • Psyllium husk: A soluble fiber that forms a viscous gel in the gut, slowing digestion and supporting SCFA production. 5–10g/day mixed into water before meals.

Daily fiber target: 30–40g total fiber, with at least 10–15g from fermentable/soluble sources. Most western adults consume 10–15g total. Increasing slowly over 2–3 weeks prevents GI adaptation symptoms.

Protein at Every Meal

High-protein meals are among the strongest acute GLP-1 secretagogues in dietary research. Amino acids directly stimulate L-cell GLP-1 release — and protein also activates peptide YY (PYY) and cholecystokinin (CCK), the other gut satiety hormones that work in concert with GLP-1.

Target: 25–40g protein per meal, prioritizing whole protein sources (eggs, meat, fish, dairy, legumes). Protein at breakfast in particular has strong evidence for improving satiety and reducing total caloric intake through the day via GLP-1 and PYY signaling.

Meal Timing: Aligning with Circadian GLP-1 Patterns

L-cell GLP-1 secretion is circadian — the same meal eaten earlier in the day produces a stronger GLP-1 response than when eaten in the evening. Studies of time-restricted eating and meal timing show that front-loading calories (larger breakfast, moderate lunch, smaller dinner) produces better post-meal glycemic profiles and higher GLP-1 responses than back-loading (smaller breakfast, large dinner) — even with the same total caloric intake.

Practical implication: don't skip breakfast. Eat your highest-protein, highest-fiber meal earlier in the day.

What to Minimize

Ultra-processed foods (UPF) directly reduce gut microbiome diversity. Emulsifiers common in processed foods (carboxymethylcellulose, polysorbate-80) have been shown in animal models to disrupt the mucus layer that Akkermansia muciniphila colonizes. Low dietary fiber intake allows SCFA-producing bacteria to decline. The gut microbiome that supports GLP-1 production is built on fermentable plant foods — not food-like products designed primarily for shelf stability and palatability engineering.

The Gut Microbiome Layer

The dietary foundation provides the substrate. The microbiome layer ensures the bacterial community that converts that substrate into GLP-1-stimulating signals is healthy, diverse, and Akkermansia-rich.

Akkermansia muciniphila: The Keystone Species

Akkermansia muciniphila is a mucin-degrading bacterium that colonizes the gut mucosa layer. Its abundance is inversely correlated with obesity, type 2 diabetes, metabolic syndrome, and gut barrier dysfunction — and positively correlated with metabolic health and longevity in centenarian microbiome studies.

Its GLP-1 relevance: the P9 surface protein pathway described above, plus the fact that Akkermansia activity at the mucosa enhances the function and sensitivity of the underlying L-cell layer.

How to support Akkermansia abundance:

  • Polyphenol-rich foods: Pomegranate, cranberry, grape polyphenols (resveratrol, ellagitannins), blueberries, and green tea catechins all selectively support Akkermansia growth. Polyphenols are metabolized by gut bacteria — Akkermansia is particularly good at utilizing them.
  • Inulin and FOS: Direct prebiotic substrate that increases Akkermansia abundance in controlled trials.
  • Intermittent fasting: During fasted periods, Akkermansia feeds on the mucin layer of the gut (it is a mucolytic bacterium). This is part of why time-restricted eating patterns support Akkermansia abundance.
  • Berberine: Berberine specifically increases Akkermansia muciniphila abundance in clinical trials — one of its most consistent microbiome effects.
  • Direct supplementation: Pasteurized (heat-killed) Akkermansia muciniphila is now available as a next-generation probiotic ingredient. Plovier et al. (2017) found that pasteurized Akkermansia actually had superior effects on gut barrier integrity and GLP-1 receptor signaling compared to live bacteria, likely because the P9 protein is more accessible. Direct supplementation addresses the gap in people who lack the gut environment to cultivate adequate Akkermansia naturally.

Berberine: The Double Mechanism

Berberine is arguably the most valuable supplement in a natural GLP-1 protocol because it works through two relevant mechanisms simultaneously:

  1. AMPK activation — overlapping with GLP-1 downstream signaling (both improve insulin sensitivity through related cellular pathways, making them synergistic)
  2. Akkermansia support — directly increasing Akkermansia abundance in the gut

Human clinical evidence for berberine's effects on blood glucose, HbA1c, lipid profiles, and gut microbiome composition is extensive and consistent. A 2019 review in the International Journal of Endocrinology confirmed berberine's specific effect on increasing Akkermansia muciniphila. Its combined metabolic and microbiome effects make it an anchor supplement for this protocol.

The Synbiotic: Building the Full Ecosystem

A synbiotic combining prebiotics (fiber substrates), probiotics (live bacterial strains), and postbiotics (beneficial metabolites) creates a more robust environment for GLP-1 pathway support than isolated components.

What to look for in a GLP-1-targeted synbiotic: - Akkermansia support: Either direct Akkermansia inclusion or demonstrated support for Akkermansia growth (inulin + polyphenol cofactors) - SCFA-producing strains: Lactobacillus and Bifidobacterium strains with documented butyrate and propionate production - Prebiotic fiber blend: Inulin + FOS + resistant starch or beta-glucan for diverse fermentation substrates - Postbiotic components: Short-chain fatty acids or their precursors, supporting the FFAR2/3 → GLP-1 signaling pathway directly

Bacillus coagulans is a spore-forming probiotic with stability advantages over most Lactobacillus strains — it survives stomach acid and heat processing reliably, and it has documented effects on the gut environment that support downstream Akkermansia colonization conditions.

The Complete Supplement Protocol

Tier 1: Daily Non-Negotiables

Synbiotic (GLP-1 targeted formula) - Include: Akkermansia support, SCFA-producing strains, prebiotic fiber blend (inulin + FOS + resistant starch), postbiotic components - Timing: With food, once or twice daily - Goal: Build and maintain the gut bacterial ecosystem that drives SCFA → GLP-1 signaling

Prebiotic fiber (additional) - Inulin powder 5–10g and/or psyllium husk 5–10g daily - Timing: With meals (particularly higher-carbohydrate meals) or in water before eating - Goal: Provide adequate fermentation substrate for SCFA-producing bacteria

Tier 2: High-Impact Additions

Berberine - Dose: 500mg, 2–3 times daily, 30 minutes before meals - Timing: Before breakfast and dinner at minimum; before lunch if taking 3x - Cycle: 4–8 weeks on, 2–4 weeks off, then repeat - Goal: AMPK activation + Akkermansia increase + blood glucose management - Note: Berberine has mild DPP-4 inhibitory activity — it partially slows GLP-1 degradation in addition to supporting production. This dual mechanism is why it is the highest-priority supplement addition after the synbiotic foundation.

Tier 3: Targeted Akkermansia Support

Pasteurized Akkermansia muciniphila (next-gen probiotic) - Dose: Per product specification (typically 10^10 cells or CFU-equivalent) - Timing: With food - Goal: Direct delivery of the P9 protein pathway mechanism, independent of the gut environment's ability to cultivate Akkermansia from dietary substrates - Particularly valuable for: people with a history of antibiotic use, poor dietary diversity, or who have tried dietary and prebiotic approaches without adequate gut microbiome improvement

Exercise and GLP-1

Exercise influences the GLP-1 pathway through two mechanisms, operating on different timescales:

Acute effect: A single bout of aerobic exercise increases plasma GLP-1 levels during and immediately after exercise, independent of food intake. The mechanism is not fully characterized but may involve muscle contraction-mediated stimulation of L-cell secretion through neurogenic or circulatory signals.

Chronic effect: Regular exercise improves GLP-1 receptor sensitivity — the downstream cellular response to each unit of GLP-1 released. This is analogous to insulin sensitization through exercise. Even if GLP-1 production doesn't increase dramatically, each pulse of GLP-1 produces a stronger metabolic response in people with higher receptor sensitivity.

Regular exercise also consistently improves gut microbiome diversity, including increases in Akkermansia muciniphila and SCFA-producing bacteria, in controlled trials. The effect is dose-dependent: 30–45 minutes of moderate-intensity exercise four to five times per week shows the most consistent microbiome benefit.

Protocol: A combination of aerobic exercise (sustained moderate intensity — 65–75% max heart rate) and resistance training is most effective. The aerobic component drives acute GLP-1 release and microbiome benefit; the resistance component drives GLUT4 translocation and independent improvements in insulin sensitivity that compound GLP-1 pathway effects.

GLPLUS+ Synbiotic supplement in a bright morning kitchen with yogurt and ginger

Fasting and Meal Timing

Fasting and time-restricted eating patterns interact with GLP-1 biology through multiple pathways:

GLP-1 receptor sensitivity: Studies of time-restricted eating (particularly early eating windows — breakfast to early afternoon) show improved GLP-1 responses to meals and better glucose management relative to isocaloric intake spread through the day, including evening eating.

Akkermansia support: During extended fasting periods (16–24+ hours), when dietary substrates are absent, Akkermansia feeds on the mucin layer of the gut epithelium. This is a normal physiological behavior and supports Akkermansia abundance in people practicing intermittent fasting. Data from caloric restriction studies consistently show higher Akkermansia in the restricted groups.

Practical recommendations: - An eating window of 8–12 hours (e.g., 7 AM to 7 PM, or 8 AM to 6 PM) aligns with circadian GLP-1 secretion patterns and supports Akkermansia growth during the fasting window - Avoid eating within 2–3 hours of bedtime — late evening eating reduces the overnight fasting period that supports gut microbiome health - If using intermittent fasting, a 16-hour fasting window (8-hour eating window) is sufficient to produce meaningful Akkermansia support effects

What to Expect: Realistic Outcomes

Week 1–2 (dietary foundation and synbiotic): Some people notice reduced afternoon energy crashes and improved post-meal satiety relatively quickly as gut bacteria begin producing more SCFAs. Others notice nothing acutely. GI adjustment is common when significantly increasing fiber intake — reduce dose and increase gradually if bloating or cramping occurs.

Weeks 2–4 (berberine addition): Post-meal blood glucose regulation often improves measurably within weeks of consistent berberine use. If you wear a continuous glucose monitor, you will typically see reduced post-meal glucose spikes and faster return to baseline. Cravings may reduce modestly.

Weeks 4–8: Akkermansia supplementation, consistent prebiotic fiber, and berberine have had time to meaningfully shift gut microbiome composition. GLP-1 pathway function is improving from the substrate level up. Many people report reduced between-meal hunger and more stable energy at this stage.

Months 2–3+: The cumulative microbiome shift is meaningful. Gut barrier integrity is improving, SCFA production is at a higher baseline, and the appetite signaling system is functioning better than at baseline. Weight management support in the context of caloric awareness becomes more accessible — the system is working with you rather than against you.

What this is not: Pharmaceutical GLP-1 receptor agonists suppress appetite dramatically within days through continuous supratherapeutic receptor activation. Natural GLP-1 support works gradually, through biological mechanisms that have a physiological ceiling. The person who expects natural GLP-1 support to produce Ozempic-equivalent appetite suppression in two weeks will be disappointed. The person who expects a meaningfully improved metabolic foundation over 60–90 days of consistent implementation will get what this protocol delivers.

Stacking the Protocol: The 30-Day Start

Week 1: Dietary Foundation

  • Target 30–35g total fiber daily, with at least 10g from fermentable sources (inulin, FOS, beta-glucan, resistant starch)
  • 25–40g protein at each meal, starting with breakfast
  • Shift eating window earlier: first meal within 2 hours of waking, last meal by 7 PM if possible
  • Eliminate or dramatically reduce ultra-processed foods and liquid calories

Week 2: Synbiotic and Berberine

  • Add GLP-1 synbiotic (Akkermansia support + SCFA-producing strains + prebiotic fiber blend) with meals daily
  • Add berberine 500mg before breakfast and dinner
  • Continue dietary foundation from Week 1

Week 3: Akkermansia-Specific Supplementation

  • Add pasteurized Akkermansia muciniphila (if not already included in the synbiotic formula) with a meal
  • Evaluate tolerability of the fiber and berberine additions — adjust dose if GI symptoms are occurring
  • Add additional polyphenol sources if not already present (pomegranate extract, resveratrol, blueberries)

Week 4: Exercise Integration

  • If not already established: add 3–4 sessions of 30–40 minute moderate-intensity aerobic exercise per week
  • If exercise is already established: consider adding a session or extending duration — incremental increases in aerobic volume consistently improve gut microbiome diversity
  • Assess: post-meal energy, hunger levels, glucose management (CGM if available), and overall satiety versus Week 1

Frequently Asked Questions

Can you increase GLP-1 without medication? Yes — meaningfully. Dietary fermentable fiber, high-protein meals, gut microbiome optimization, and targeted supplementation (berberine, synbiotic, Akkermansia support) all have documented effects on GLP-1 secretion and GLP-1 pathway function. The increase is physiological, not pharmacological — real improvements to a real biological system, within the ceiling of natural production capacity.

What is the "natural version of Ozempic"? This framing, while popular, is misleading because it implies comparable effects. There is no natural equivalent to the supratherapeutic, continuous GLP-1 receptor stimulation that injectable GLP-1 agonists produce. What exists is a set of evidence-based tools for optimizing the GLP-1 pathway the body already has — primarily gut microbiome support (Akkermansia, SCFA-producing bacteria) and berberine. These are legitimate metabolic health interventions with their own evidence base.

Does berberine increase GLP-1? Berberine influences the GLP-1 pathway through two mechanisms: it increases Akkermansia muciniphila abundance (which supports GLP-1 secretion) and it has mild DPP-4 inhibitory activity (slowing GLP-1 degradation). Human trials show consistent improvements in post-meal glucose management, HbA1c, and insulin sensitivity consistent with improved GLP-1 pathway function.

What foods increase GLP-1? High-protein foods (eggs, meat, fish, legumes) produce strong acute GLP-1 responses through direct L-cell amino acid sensing. Fermentable fiber foods (oats, legumes, garlic, onions, asparagus, Jerusalem artichoke) support chronic GLP-1 through the SCFA pathway. Polyphenol-rich foods (pomegranate, blueberries, cranberries, green tea) support Akkermansia abundance, which enhances GLP-1 secretion over time.

How long does it take to increase GLP-1 naturally? Acute dietary effects (protein, fiber at a meal) occur within hours. Gut microbiome shifts that increase baseline GLP-1 pathway function take 4–8 weeks of consistent dietary and supplementation changes. The cumulative metabolic effects — reduced cravings, improved satiety, better glucose management — are most noticeable at 6–12 weeks of consistent implementation.

Does gut bacteria affect GLP-1? Yes, substantially. The SCFA pathway (gut bacteria fermenting fiber into butyrate/propionate/acetate → FFAR2/3 → L-cell → GLP-1) is one of the primary chronic regulators of GLP-1 production capacity. Akkermansia muciniphila specifically increases GLP-1 secretion through the P9 protein → ICAM-2 pathway. Gut microbiome composition is arguably the most important single variable in natural GLP-1 pathway function.

Key Takeaways

  • GLP-1 is produced by L-cells in response to nutrients, SCFAs from gut bacteria, and the Akkermansia P9 protein pathway — all of which are targetable through diet and supplementation.
  • Fermentable fiber is the single most important dietary intervention for supporting the SCFA → GLP-1 pathway over time. 30–40g total fiber daily, with 10–15g fermentable, is the target.
  • Akkermansia muciniphila is the keystone species for GLP-1 pathway support — and is targetable through polyphenol-rich foods, inulin, berberine, intermittent fasting, and direct supplementation.
  • Berberine is the highest-impact supplement in this protocol: it increases Akkermansia abundance, activates AMPK (overlapping with GLP-1 downstream pathways), and has mild DPP-4 inhibitory activity.
  • Protein at every meal is a non-negotiable — it is one of the strongest acute GLP-1 secretagogues available through diet.
  • Natural GLP-1 support is not a pharmaceutical equivalent. Set expectations for meaningful metabolic improvement over 6–12 weeks, not dramatic appetite suppression in two weeks.
  • The 30-day protocol: Week 1 diet, Week 2 synbiotic + berberine, Week 3 Akkermansia supplementation, Week 4 exercise integration. Build incrementally and assess.

Related Reading

  • How to Build a Supplement Stack: A Science-Based Framework
  • The Longevity Protocol: A Science-Based Supplement Stack for Cellular Health in 2026
  • The Gut Microbiome and Metabolic Health: What Akkermansia Actually Does
  • Why Fermentable Fiber Matters More Than Any Supplement

Evidence References

  • Drucker DJ. "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism. 2018.
  • Plovier H, et al. "A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium blunts colitis associated tumourigenesis by restoring a semi-permeable colonic barrier in mice." Nature Medicine. 2017.
  • Plovier H, et al. "Akkermansia muciniphila and improved metabolic health during caloric restriction." Nature Medicine. 2017.
  • Depommier C, et al. "Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study." Nature Medicine. 2019.
  • Everard A, et al. "Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity." PNAS. 2013.
  • Tong Y, et al. "Berberine enhances intestinal mucosal barrier function and Akkermansia muciniphila." International Journal of Endocrinology. 2019.
  • Chambers ES, et al. "Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity." Gut. 2015.
  • Reimer RA, et al. "Mechanisms of the effects of dietary fiber on GLP-1 secretion." Advances in Nutrition. 2019.
  • Staels B, Kuipers F. "Bile acid sequestrants and the treatment of type 2 diabetes mellitus." Drugs. 2007.
  • Jakubowicz D, et al. "High caloric intake at breakfast vs. dinner differentially influences weight loss by altering postprandial insulin secretion and GLP-1 response." Obesity. 2013.
  • Barton W, et al. "The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level." Gut. 2018.
  • Clark A, Mach N. "Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes." Journal of the International Society of Sports Nutrition. 2016.
  • Yin J, et al. "Berberine improves glucose metabolism through induction of glycolysis." American Journal of Physiology – Endocrinology and Metabolism. 2008.
  • Holst JJ. "The physiology of glucagon-like peptide 1." Physiological Reviews. 2007.
  • Sutton EF, et al. "Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes." Cell Metabolism. 2018.